Posted by Michael Wonder on 10 Jan 2019
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
10 January 2019 - PHARMAC is pleased to announce its decision to approve a multi-product agreement with Merck Sharpe & Dohme.
This will result in the listing of a new, once-daily presentation of raltegravir for the treatment of HIV, once it is registered with Medsafe, as well as changes to the contractual arrangements for the currently funded presentations of raltegravir and posaconazole.
The confidential rebates that apply to both posaconazole (Noxafil) presentations (tab modified-release 100 mg modified release tablets and 40 mg/mL oral liquid) will be changed from 1 February 2019. The effect of this will be to reduce the net cost of posaconazole.
